Immunovant stock falls 8% amid Graves' disease program update Sep. 09, 2024 5:18 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
Immunovant, Inc. (IMVT)
Company Research
Source: Seeking Alpha
of Graves' disease, adding the FDA has cleared it to begin a pivotal trial of its drug candidate IMVT-1402 for the same disease. The biotech company said the Phase 2a study showed high dose batoclimab achieved a 76% response rate in patients who were uncontrolled on anti-thyroid drugs at week 12. Immunovant also said the FDA has cleared its Investigational New Drug application for a pivotal trial of IMVT-1402 in the treatment of Graves' disease. The study is expected to begin by the end of the year, according to a statement Citi said in a note on Monday that Immunovant remains one of its top picks, calling the Phase 2 data encouraging. The investment bank raised its price target to $60 from $51. Immunovant is a subsidiary of Roivant ( NASDAQ: ROIV Recommended For You More Trending News Recommended For You More Trending News Related Stocks In The News Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
- Immunovant, Inc. (NASDAQ: IMVT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? [Yahoo! Finance]Yahoo! Finance
- IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab [Yahoo! Finance]Yahoo! Finance
- Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 8/6/24 - Miss
IMVT
Sec Filings
- 9/9/24 - Form 8-K
- 8/23/24 - Form 4
- 8/23/24 - Form 4
- IMVT's page on the SEC website